Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms

Jammal,Millena Prata; Araújo da Silva,Allison; Martins Filho,Agrimaldo; de Castro Côbo,Eliângela; Adad,Sheila Jorge; Murta,Eddie Fernando Candido; Nomelini,Rosekeila Simões

doi:10.3892/ol.2014.2781

Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms

Authors:
- Millena Prata Jammal
- Allison Araújo da Silva
- Agrimaldo Martins Filho
- Eliângela de Castro Côbo
- Sheila Jorge Adad
- Eddie Fernando Candido Murta
- Rosekeila Simões Nomelini
View Affiliations

Affiliations: Research Institute of Oncology (IPON)/Discipline of Gynecology and Obstetrics, Federal University of Triângulo Mineiro (UFTM), 38025-440 Uberaba, MG, Brazil, Department of Special Pathology, Federal University of Triângulo Mineiro (UFTM), 38025-440 Uberaba, MG, Brazil
Published online on: December 8, 2014 https://doi.org/10.3892/ol.2014.2781
Pages: 979-983

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the ninth most common malignancy and the fifth leading cause of cancer death in women in the USA. The majority of malignant tumors of the ovary are diagnosed at an advanced stage, making it the most fatal gynecological cancer. The aim of the current study was to determine whether there are differences in immunohistochemical tissue staining of cytokine tumor necrosis factor‑α (TNF‑α) and interleukin‑10 (IL‑10) between benign tumors and malignant primary ovarian cancer. In total, 28 patients undergoing surgery for ovarian cysts were evaluated, and a diagnosis of benign neoplasm (n=14) or malignant neoplasm (n=14) was determined. An immunohistochemical study of histological sections of ovarian tumors was conducted. The results were analyzed using Fisher's exact test, with P<0.05 indicating a statistically significant difference. Immunohistochemical staining of IL‑10 was increased in malignant tumors compared with benign tumors (P=0.0128). For TNF‑α, the immunohistochemical staining was more intense in malignant neoplasms, however, a statistically significant difference was not observed. These results indicate that the analysis of cytokines may be useful as a potential tissue marker of ovarian malignancy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Dørum A, Kristensen GB, Abeler VM, Tropé CG and Møller P: Early detection of familial ovarian cancer. Eur J Cancer. 32A:1645–1651. 1996. View Article : Google Scholar : PubMed/NCBI
3	Yawn BP, Wollan P, Klee M and Barrette B: Ovarian carcinoma: care and survival in a community-based population. Clin Ther. 23:146–159. 2001. View Article : Google Scholar : PubMed/NCBI
4	Padilla LA, Radosevich DM and Milad MP: Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet. 88:84–88. 2005. View Article : Google Scholar
5	Minaretzis D, Tsionou C, Tziortziotis D, Michalas S and Aravantinos D: Ovarian tumors: prediction of the probability of malignancy by using patient’s age and tumor morphologic features with a logistic model. Gynecol Obstet Invest. 38:140–144. 1994. View Article : Google Scholar
6	Osmers RG, Osmers M, von Maydell B, Wagner B and Kuhn W: Evaluation of ovarian tumors in post-menopausal women by transvaginal sonography. Eur J Obstet Gynecol Reprod Biol. 77:81–88. 1998. View Article : Google Scholar : PubMed/NCBI
7	Guerriero S, Ajossa S, Garau N, et al: Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol. 192:401–406. 2005. View Article : Google Scholar : PubMed/NCBI
8	Szpurek D, Moszyniki R, Zietkowiak W, et al: An ultrasonographic morphological index for prediction of ovarian tumor malignancy. Eur Gynaecol Oncol. 26:51–54. 2005.
9	U.S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Ann Fam Med. 2:260–262. 2004. View Article : Google Scholar : PubMed/NCBI
10	Fishman DA, Cohen L, Blank SV, et al: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 192:1214–1222. 2005. View Article : Google Scholar : PubMed/NCBI
11	Negus RP, Stamp GW, Hadley J and Balkwill FR: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol. 150:1723–1734. 1997.PubMed/NCBI
12	Mantovani G, Macciò A, Pisano M, et al: Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 71:724–731. 1997. View Article : Google Scholar : PubMed/NCBI
13	Dobrzycka B, Terlikowski SJ, Kowalczuk O and Kinalski M: Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw. 20:131–134. 2009.PubMed/NCBI
14	Charles KA, Kulbe H, Soper R, et al: The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 119:3011–3023. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhou J, Ye F, Chen H, Lv W and Gan N: The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res. 35:290–300. 2007. View Article : Google Scholar : PubMed/NCBI
16	Tavares-Murta BM, de Cunha FQ, Miranda R, Adad SJ and Murta EFC: Differential tumor microenvironment in human ovarian cystic tumors. Tumori. 90:491–497. 2004.
17	Murta EF, da Silva CS, Gomes RA, et al: Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients. Eur J Gynaecol Oncol. 25:707–712. 2004.PubMed/NCBI
18	Murta EF and Nomelini RS: Early diagnosis and predictors of malignancy of adnexal masses. Curr Opin Obstet Gynecol. 18:14–19. 2006. View Article : Google Scholar : PubMed/NCBI
19	No authors listed. International Federation of Gynecology and Obstetrics annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet. 28:189–190. 1993.
20	Szlosarek PW, Grimshaw MJ, Kulbe H, et al: Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther. 5:382–390. 2006. View Article : Google Scholar : PubMed/NCBI
21	Sethi G, Sung B and Aggarwal BB: TNF: a master switch for inflammation to cancer. Front Biosci. 13:5094–5107. 2008. View Article : Google Scholar : PubMed/NCBI
22	Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13:135–14. 2002. View Article : Google Scholar : PubMed/NCBI
23	Bertazza L and Mocellin S: Tumor necrosis factor (TNF) biology and cell death. Front Biosci. 13:2736–2743. 2008. View Article : Google Scholar
24	Anderson GM, Nakada MT and DeWitte M: Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 4:314–320. 2004. View Article : Google Scholar : PubMed/NCBI
25	Szlosarek PW, Grimshaw MJ, Wilbanks GD, et al: Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer. 121:6–11. 2007. View Article : Google Scholar : PubMed/NCBI
26	Gadducci A, Ferdeghini M, Castellani C, et al: Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol Oncol. 58:184–188. 1995. View Article : Google Scholar : PubMed/NCBI
27	Radke J, Schmidt D, Böhme M, et al: Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd. 56:83–87. 1996.(in German). View Article : Google Scholar : PubMed/NCBI
28	Hassan F, Islam S, Tumurkhuu G, et al: Involvement of interleukin-1 receptor-associated kinase (IRAK)-M in toll-like receptor (TLR) 7-mediated tolerance in RAW 264.7 macrophage-like cells. Cell Immunol. 256:99–103. 2009. View Article : Google Scholar : PubMed/NCBI
29	Nowak M, Klink M, Glowacka E, et al: Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol. 71:91–98. 2010. View Article : Google Scholar : PubMed/NCBI
30	Daraï E, Detchev R, Hugol D and Quang NT: Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 18:1681–685. 2003. View Article : Google Scholar : PubMed/NCBI
31	Kozłowski L, Zakrzewska I, Tokajuk P and Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 48:82–84. 2003.
32	Rabinovich A, Medina L, Piura B and Huleihel M: Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw. 21:122–128. 2010.PubMed/NCBI
33	Yigit R, Massuger LF, Figdor CG and Torensma R: Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 117:366–72. 2010. View Article : Google Scholar : PubMed/NCBI
34	Gao G, Sun J, Gao J, Xiong L, Yu L and Gao Y: Chronic stress promoted the growth of ovarian carcinoma via increasing serum levels of norepinephrine and interleukin-10 and altering nm23 and NDRG1 expression in tumor tissues in nude mice. Biosci Trends. 7:56–63. 2013.PubMed/NCBI
35	Liu CZ, Zhang L, Chang XH, et al: Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res. 24:130–137. 2012. View Article : Google Scholar